nodes	percent_of_prediction	percent_of_DWPC	metapath
Flecainide—CYP2D6—Temsirolimus—kidney cancer	0.13	0.25	CbGbCtD
Flecainide—CYP2C9—Capecitabine—kidney cancer	0.0776	0.15	CbGbCtD
Flecainide—CYP2D6—Pazopanib—kidney cancer	0.068	0.131	CbGbCtD
Flecainide—CYP2C9—Paclitaxel—kidney cancer	0.0486	0.0938	CbGbCtD
Flecainide—CYP2D6—Erlotinib—kidney cancer	0.0485	0.0937	CbGbCtD
Flecainide—CYP2C9—Sorafenib—kidney cancer	0.0432	0.0833	CbGbCtD
Flecainide—CYP2D6—Sorafenib—kidney cancer	0.0395	0.0762	CbGbCtD
Flecainide—CYP2D6—Vinblastine—kidney cancer	0.039	0.0753	CbGbCtD
Flecainide—CYP2D6—Doxorubicin—kidney cancer	0.024	0.0462	CbGbCtD
Flecainide—Mefloquine—ACHE—kidney cancer	0.00784	0.55	CrCbGaD
Flecainide—SCN4A—Interaction between L1 and Ankyrins—SPTBN4—kidney cancer	0.00495	0.0833	CbGpPWpGaD
Flecainide—SCN4A—Interaction between L1 and Ankyrins—L1CAM—kidney cancer	0.00495	0.0833	CbGpPWpGaD
Flecainide—Mefloquine—BCHE—kidney cancer	0.00461	0.323	CrCbGaD
Flecainide—SCN5A—Interaction between L1 and Ankyrins—SPTBN4—kidney cancer	0.00335	0.0565	CbGpPWpGaD
Flecainide—SCN5A—Interaction between L1 and Ankyrins—L1CAM—kidney cancer	0.00335	0.0565	CbGpPWpGaD
Flecainide—SCN4A—L1CAM interactions—L1CAM—kidney cancer	0.0019	0.032	CbGpPWpGaD
Flecainide—SCN4A—L1CAM interactions—SPTBN4—kidney cancer	0.0019	0.032	CbGpPWpGaD
Flecainide—Mefloquine—ABCB1—kidney cancer	0.00181	0.127	CrCbGaD
Flecainide—CYP2D6—Fatty Acid Omega Oxidation—ALDH1A1—kidney cancer	0.00133	0.0224	CbGpPWpGaD
Flecainide—SCN5A—L1CAM interactions—SPTBN4—kidney cancer	0.00129	0.0217	CbGpPWpGaD
Flecainide—SCN5A—L1CAM interactions—L1CAM—kidney cancer	0.00129	0.0217	CbGpPWpGaD
Flecainide—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—kidney cancer	0.00104	0.0175	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—UNC5C—kidney cancer	0.000947	0.0159	CbGpPWpGaD
Flecainide—SCN5A—Cardiac Progenitor Differentiation—PAX6—kidney cancer	0.000915	0.0154	CbGpPWpGaD
Flecainide—CYP2D6—Codeine and Morphine Metabolism—ABCB1—kidney cancer	0.000892	0.015	CbGpPWpGaD
Flecainide—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—kidney cancer	0.000814	0.0137	CbGpPWpGaD
Flecainide—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—kidney cancer	0.000741	0.0125	CbGpPWpGaD
Flecainide—SCN4A—L1CAM interactions—PAK1—kidney cancer	0.000728	0.0123	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—SPTBN4—kidney cancer	0.000718	0.0121	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—L1CAM—kidney cancer	0.000718	0.0121	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—UNC5C—kidney cancer	0.000676	0.0114	CbGpPWpGaD
Flecainide—SCN5A—Cardiac Progenitor Differentiation—IGF2—kidney cancer	0.000649	0.0109	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—UNC5C—kidney cancer	0.000642	0.0108	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—SPTBN4—kidney cancer	0.000512	0.00862	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—L1CAM—kidney cancer	0.000512	0.00862	CbGpPWpGaD
Flecainide—SCN5A—Cardiac Progenitor Differentiation—KDR—kidney cancer	0.000494	0.00832	CbGpPWpGaD
Flecainide—SCN5A—L1CAM interactions—PAK1—kidney cancer	0.000493	0.00831	CbGpPWpGaD
Flecainide—SCN5A—SIDS Susceptibility Pathways—HSPD1—kidney cancer	0.000492	0.00828	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—L1CAM—kidney cancer	0.000487	0.00819	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—SPTBN4—kidney cancer	0.000487	0.00819	CbGpPWpGaD
Flecainide—CYP2D6—Melatonin metabolism and effects—ACHE—kidney cancer	0.000485	0.00817	CbGpPWpGaD
Flecainide—CYP2D6—Fatty Acid Omega Oxidation—CYP1A1—kidney cancer	0.000472	0.00794	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—UNC5C—kidney cancer	0.000458	0.00771	CbGpPWpGaD
Flecainide—SCN5A—Cardiac Progenitor Differentiation—KIT—kidney cancer	0.000455	0.00766	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—CER1—kidney cancer	0.000448	0.00754	CbGpPWpGaD
Flecainide—SCN5A—SIDS Susceptibility Pathways—IL13—kidney cancer	0.000413	0.00695	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—HNF1A—kidney cancer	0.000405	0.00682	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—EPAS1—kidney cancer	0.000405	0.00682	CbGpPWpGaD
Flecainide—CYP2D6—Xenobiotics—CYP1A1—kidney cancer	0.000394	0.00664	CbGpPWpGaD
Flecainide—CYP2C9—Xenobiotics—CYP1A1—kidney cancer	0.000391	0.00659	CbGpPWpGaD
Flecainide—CYP2D6—Tamoxifen metabolism—CYP1A1—kidney cancer	0.000379	0.00639	CbGpPWpGaD
Flecainide—CYP2C9—Tamoxifen metabolism—CYP1A1—kidney cancer	0.000376	0.00633	CbGpPWpGaD
Flecainide—CYP2D6—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	0.000374	0.0063	CbGpPWpGaD
Flecainide—CYP2C9—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	0.000371	0.00625	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—ACY1—kidney cancer	0.000363	0.00611	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—ACY1—kidney cancer	0.00036	0.00606	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—L1CAM—kidney cancer	0.000347	0.00585	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—SPTBN4—kidney cancer	0.000347	0.00585	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—HNF1B—kidney cancer	0.00033	0.00556	CbGpPWpGaD
Flecainide—SCN5A—SIDS Susceptibility Pathways—EGR1—kidney cancer	0.000313	0.00527	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—CER1—kidney cancer	0.000303	0.00511	CbGpPWpGaD
Flecainide—Decreased appetite—Vincristine—kidney cancer	0.000299	0.000732	CcSEcCtD
Flecainide—Pruritus—Sorafenib—kidney cancer	0.000299	0.000732	CcSEcCtD
Flecainide—Vomiting—Erlotinib—kidney cancer	0.000299	0.000731	CcSEcCtD
Flecainide—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000297	0.000728	CcSEcCtD
Flecainide—Gastrointestinal disorder—Vincristine—kidney cancer	0.000297	0.000727	CcSEcCtD
Flecainide—Fatigue—Vincristine—kidney cancer	0.000297	0.000726	CcSEcCtD
Flecainide—Rash—Erlotinib—kidney cancer	0.000296	0.000725	CcSEcCtD
Flecainide—Dermatitis—Erlotinib—kidney cancer	0.000296	0.000725	CcSEcCtD
Flecainide—Palpitations—Paclitaxel—kidney cancer	0.000296	0.000724	CcSEcCtD
Flecainide—Insomnia—Gemcitabine—kidney cancer	0.000295	0.000723	CcSEcCtD
Flecainide—Eye disorder—Capecitabine—kidney cancer	0.000295	0.000722	CcSEcCtD
Flecainide—Headache—Erlotinib—kidney cancer	0.000294	0.000721	CcSEcCtD
Flecainide—Tinnitus—Capecitabine—kidney cancer	0.000294	0.00072	CcSEcCtD
Flecainide—Loss of consciousness—Paclitaxel—kidney cancer	0.000294	0.00072	CcSEcCtD
Flecainide—Pain—Vincristine—kidney cancer	0.000294	0.00072	CcSEcCtD
Flecainide—Constipation—Vincristine—kidney cancer	0.000294	0.00072	CcSEcCtD
Flecainide—Gastrointestinal haemorrhage—Doxorubicin—kidney cancer	0.000294	0.00072	CcSEcCtD
Flecainide—Diplopia—Doxorubicin—kidney cancer	0.000294	0.00072	CcSEcCtD
Flecainide—CYP2D6—Melatonin metabolism and effects—CYP1A1—kidney cancer	0.000293	0.00493	CbGpPWpGaD
Flecainide—Paraesthesia—Gemcitabine—kidney cancer	0.000293	0.000717	CcSEcCtD
Flecainide—Flushing—Capecitabine—kidney cancer	0.000293	0.000717	CcSEcCtD
Flecainide—Cough—Paclitaxel—kidney cancer	0.000292	0.000715	CcSEcCtD
Flecainide—Asthenia—Sunitinib—kidney cancer	0.000292	0.000714	CcSEcCtD
Flecainide—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	0.000292	0.00491	CbGpPWpGaD
Flecainide—CYP2C9—Arachidonic acid metabolism—PTGS1—kidney cancer	0.000292	0.00491	CbGpPWpGaD
Flecainide—Dyspnoea—Gemcitabine—kidney cancer	0.000291	0.000712	CcSEcCtD
Flecainide—Nausea—Vinblastine—kidney cancer	0.00029	0.000711	CcSEcCtD
Flecainide—Somnolence—Gemcitabine—kidney cancer	0.00029	0.00071	CcSEcCtD
Flecainide—Convulsion—Paclitaxel—kidney cancer	0.00029	0.00071	CcSEcCtD
Flecainide—Nausea—Everolimus—kidney cancer	0.000289	0.000708	CcSEcCtD
Flecainide—Diarrhoea—Sorafenib—kidney cancer	0.000289	0.000708	CcSEcCtD
Flecainide—Hypertension—Paclitaxel—kidney cancer	0.000289	0.000708	CcSEcCtD
Flecainide—Pruritus—Sunitinib—kidney cancer	0.000288	0.000704	CcSEcCtD
Flecainide—Immune system disorder—Capecitabine—kidney cancer	0.000285	0.000698	CcSEcCtD
Flecainide—Arthralgia—Paclitaxel—kidney cancer	0.000285	0.000698	CcSEcCtD
Flecainide—Myalgia—Paclitaxel—kidney cancer	0.000285	0.000698	CcSEcCtD
Flecainide—Chest pain—Paclitaxel—kidney cancer	0.000285	0.000698	CcSEcCtD
Flecainide—Anxiety—Paclitaxel—kidney cancer	0.000284	0.000695	CcSEcCtD
Flecainide—Decreased appetite—Gemcitabine—kidney cancer	0.000284	0.000695	CcSEcCtD
Flecainide—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000283	0.000693	CcSEcCtD
Flecainide—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000282	0.00069	CcSEcCtD
Flecainide—Discomfort—Paclitaxel—kidney cancer	0.000282	0.000689	CcSEcCtD
Flecainide—Fatigue—Gemcitabine—kidney cancer	0.000281	0.000689	CcSEcCtD
Flecainide—Gastrointestinal pain—Vincristine—kidney cancer	0.000281	0.000689	CcSEcCtD
Flecainide—Cardiac arrest—Doxorubicin—kidney cancer	0.00028	0.000685	CcSEcCtD
Flecainide—Dizziness—Sorafenib—kidney cancer	0.000279	0.000684	CcSEcCtD
Flecainide—Pain—Gemcitabine—kidney cancer	0.000279	0.000683	CcSEcCtD
Flecainide—Constipation—Gemcitabine—kidney cancer	0.000279	0.000683	CcSEcCtD
Flecainide—Nausea—Erlotinib—kidney cancer	0.000279	0.000683	CcSEcCtD
Flecainide—Alopecia—Capecitabine—kidney cancer	0.000279	0.000683	CcSEcCtD
Flecainide—Dry mouth—Paclitaxel—kidney cancer	0.000279	0.000682	CcSEcCtD
Flecainide—Diarrhoea—Sunitinib—kidney cancer	0.000278	0.000681	CcSEcCtD
Flecainide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	0.000278	0.00468	CbGpPWpGaD
Flecainide—Ataxia—Doxorubicin—kidney cancer	0.000276	0.000677	CcSEcCtD
Flecainide—Asthenia—Dactinomycin—kidney cancer	0.000276	0.000676	CcSEcCtD
Flecainide—Confusional state—Paclitaxel—kidney cancer	0.000275	0.000674	CcSEcCtD
Flecainide—SCN4A—Axon guidance—PAK1—kidney cancer	0.000275	0.00463	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—EPAS1—kidney cancer	0.000274	0.00462	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—HNF1A—kidney cancer	0.000274	0.00462	CbGpPWpGaD
Flecainide—Oedema—Paclitaxel—kidney cancer	0.000273	0.000669	CcSEcCtD
Flecainide—Abdominal pain—Vincristine—kidney cancer	0.000272	0.000666	CcSEcCtD
Flecainide—Body temperature increased—Vincristine—kidney cancer	0.000272	0.000666	CcSEcCtD
Flecainide—Flatulence—Capecitabine—kidney cancer	0.000271	0.000663	CcSEcCtD
Flecainide—Dysgeusia—Capecitabine—kidney cancer	0.000269	0.000659	CcSEcCtD
Flecainide—Dizziness—Sunitinib—kidney cancer	0.000269	0.000658	CcSEcCtD
Flecainide—Feeling abnormal—Gemcitabine—kidney cancer	0.000269	0.000658	CcSEcCtD
Flecainide—Shock—Paclitaxel—kidney cancer	0.000269	0.000658	CcSEcCtD
Flecainide—Vomiting—Sorafenib—kidney cancer	0.000269	0.000658	CcSEcCtD
Flecainide—Nervous system disorder—Paclitaxel—kidney cancer	0.000268	0.000656	CcSEcCtD
Flecainide—Thrombocytopenia—Paclitaxel—kidney cancer	0.000267	0.000655	CcSEcCtD
Flecainide—Tachycardia—Paclitaxel—kidney cancer	0.000267	0.000653	CcSEcCtD
Flecainide—Rash—Sorafenib—kidney cancer	0.000266	0.000652	CcSEcCtD
Flecainide—Dermatitis—Sorafenib—kidney cancer	0.000266	0.000652	CcSEcCtD
Flecainide—Skin disorder—Paclitaxel—kidney cancer	0.000265	0.00065	CcSEcCtD
Flecainide—Headache—Sorafenib—kidney cancer	0.000265	0.000648	CcSEcCtD
Flecainide—Hyperhidrosis—Paclitaxel—kidney cancer	0.000264	0.000647	CcSEcCtD
Flecainide—Diarrhoea—Dactinomycin—kidney cancer	0.000263	0.000645	CcSEcCtD
Flecainide—Anorexia—Paclitaxel—kidney cancer	0.00026	0.000638	CcSEcCtD
Flecainide—Vision blurred—Capecitabine—kidney cancer	0.000259	0.000634	CcSEcCtD
Flecainide—Vomiting—Sunitinib—kidney cancer	0.000259	0.000633	CcSEcCtD
Flecainide—Body temperature increased—Gemcitabine—kidney cancer	0.000258	0.000632	CcSEcCtD
Flecainide—Tremor—Capecitabine—kidney cancer	0.000257	0.00063	CcSEcCtD
Flecainide—Rash—Sunitinib—kidney cancer	0.000256	0.000628	CcSEcCtD
Flecainide—Dermatitis—Sunitinib—kidney cancer	0.000256	0.000627	CcSEcCtD
Flecainide—Hypotension—Paclitaxel—kidney cancer	0.000255	0.000625	CcSEcCtD
Flecainide—Ill-defined disorder—Capecitabine—kidney cancer	0.000255	0.000624	CcSEcCtD
Flecainide—Headache—Sunitinib—kidney cancer	0.000255	0.000624	CcSEcCtD
Flecainide—Nausea—Sorafenib—kidney cancer	0.000251	0.000615	CcSEcCtD
Flecainide—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000249	0.000609	CcSEcCtD
Flecainide—Malaise—Capecitabine—kidney cancer	0.000248	0.000607	CcSEcCtD
Flecainide—Angina pectoris—Doxorubicin—kidney cancer	0.000248	0.000606	CcSEcCtD
Flecainide—Insomnia—Paclitaxel—kidney cancer	0.000247	0.000605	CcSEcCtD
Flecainide—Vertigo—Capecitabine—kidney cancer	0.000247	0.000604	CcSEcCtD
Flecainide—Asthenia—Vincristine—kidney cancer	0.000247	0.000604	CcSEcCtD
Flecainide—Syncope—Capecitabine—kidney cancer	0.000246	0.000603	CcSEcCtD
Flecainide—Leukopenia—Capecitabine—kidney cancer	0.000246	0.000602	CcSEcCtD
Flecainide—Paraesthesia—Paclitaxel—kidney cancer	0.000245	0.000601	CcSEcCtD
Flecainide—Vomiting—Dactinomycin—kidney cancer	0.000245	0.000599	CcSEcCtD
Flecainide—Dyspnoea—Paclitaxel—kidney cancer	0.000244	0.000596	CcSEcCtD
Flecainide—Somnolence—Paclitaxel—kidney cancer	0.000243	0.000595	CcSEcCtD
Flecainide—Palpitations—Capecitabine—kidney cancer	0.000243	0.000594	CcSEcCtD
Flecainide—Rash—Dactinomycin—kidney cancer	0.000243	0.000594	CcSEcCtD
Flecainide—Nausea—Sunitinib—kidney cancer	0.000242	0.000591	CcSEcCtD
Flecainide—Loss of consciousness—Capecitabine—kidney cancer	0.000241	0.000591	CcSEcCtD
Flecainide—Dyspepsia—Paclitaxel—kidney cancer	0.00024	0.000589	CcSEcCtD
Flecainide—Cough—Capecitabine—kidney cancer	0.00024	0.000587	CcSEcCtD
Flecainide—Dysuria—Doxorubicin—kidney cancer	0.000238	0.000582	CcSEcCtD
Flecainide—Decreased appetite—Paclitaxel—kidney cancer	0.000237	0.000582	CcSEcCtD
Flecainide—Hypertension—Capecitabine—kidney cancer	0.000237	0.000581	CcSEcCtD
Flecainide—SCN4A—Developmental Biology—CTNNA1—kidney cancer	0.000237	0.00398	CbGpPWpGaD
Flecainide—SCN4A—L1CAM interactions—MAPK3—kidney cancer	0.000236	0.00398	CbGpPWpGaD
Flecainide—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000236	0.000578	CcSEcCtD
Flecainide—Fatigue—Paclitaxel—kidney cancer	0.000236	0.000577	CcSEcCtD
Flecainide—Diarrhoea—Vincristine—kidney cancer	0.000235	0.000576	CcSEcCtD
Flecainide—Asthenia—Gemcitabine—kidney cancer	0.000234	0.000573	CcSEcCtD
Flecainide—Arthralgia—Capecitabine—kidney cancer	0.000234	0.000573	CcSEcCtD
Flecainide—Myalgia—Capecitabine—kidney cancer	0.000234	0.000573	CcSEcCtD
Flecainide—Chest pain—Capecitabine—kidney cancer	0.000234	0.000573	CcSEcCtD
Flecainide—Pain—Paclitaxel—kidney cancer	0.000234	0.000572	CcSEcCtD
Flecainide—Constipation—Paclitaxel—kidney cancer	0.000234	0.000572	CcSEcCtD
Flecainide—Anxiety—Capecitabine—kidney cancer	0.000233	0.000571	CcSEcCtD
Flecainide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000232	0.000569	CcSEcCtD
Flecainide—Photosensitivity reaction—Doxorubicin—kidney cancer	0.000232	0.000568	CcSEcCtD
Flecainide—Discomfort—Capecitabine—kidney cancer	0.000231	0.000566	CcSEcCtD
Flecainide—Pruritus—Gemcitabine—kidney cancer	0.000231	0.000565	CcSEcCtD
Flecainide—Hyperglycaemia—Doxorubicin—kidney cancer	0.000229	0.000561	CcSEcCtD
Flecainide—Dry mouth—Capecitabine—kidney cancer	0.000229	0.00056	CcSEcCtD
Flecainide—Nausea—Dactinomycin—kidney cancer	0.000229	0.00056	CcSEcCtD
Flecainide—Pneumonia—Doxorubicin—kidney cancer	0.000228	0.000558	CcSEcCtD
Flecainide—Dizziness—Vincristine—kidney cancer	0.000227	0.000557	CcSEcCtD
Flecainide—SCN4A—Developmental Biology—PAX6—kidney cancer	0.000226	0.00381	CbGpPWpGaD
Flecainide—Confusional state—Capecitabine—kidney cancer	0.000226	0.000554	CcSEcCtD
Flecainide—Feeling abnormal—Paclitaxel—kidney cancer	0.000225	0.000551	CcSEcCtD
Flecainide—SCN4A—L1CAM interactions—MAPK1—kidney cancer	0.000225	0.00378	CbGpPWpGaD
Flecainide—Oedema—Capecitabine—kidney cancer	0.000224	0.000549	CcSEcCtD
Flecainide—SCN5A—Developmental Biology—HNF1B—kidney cancer	0.000224	0.00377	CbGpPWpGaD
Flecainide—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000223	0.000547	CcSEcCtD
Flecainide—Diarrhoea—Gemcitabine—kidney cancer	0.000223	0.000547	CcSEcCtD
Flecainide—Renal failure—Doxorubicin—kidney cancer	0.000223	0.000545	CcSEcCtD
Flecainide—Neuropathy peripheral—Doxorubicin—kidney cancer	0.000222	0.000544	CcSEcCtD
Flecainide—Jaundice—Doxorubicin—kidney cancer	0.000221	0.000541	CcSEcCtD
Flecainide—Shock—Capecitabine—kidney cancer	0.000221	0.00054	CcSEcCtD
Flecainide—Nervous system disorder—Capecitabine—kidney cancer	0.00022	0.000538	CcSEcCtD
Flecainide—Thrombocytopenia—Capecitabine—kidney cancer	0.00022	0.000537	CcSEcCtD
Flecainide—Tachycardia—Capecitabine—kidney cancer	0.000219	0.000536	CcSEcCtD
Flecainide—Vomiting—Vincristine—kidney cancer	0.000219	0.000535	CcSEcCtD
Flecainide—Skin disorder—Capecitabine—kidney cancer	0.000218	0.000533	CcSEcCtD
Flecainide—SCN5A—SIDS Susceptibility Pathways—HIF1A—kidney cancer	0.000218	0.00367	CbGpPWpGaD
Flecainide—Urticaria—Paclitaxel—kidney cancer	0.000217	0.000531	CcSEcCtD
Flecainide—Rash—Vincristine—kidney cancer	0.000217	0.000531	CcSEcCtD
Flecainide—Hyperhidrosis—Capecitabine—kidney cancer	0.000217	0.000531	CcSEcCtD
Flecainide—Dermatitis—Vincristine—kidney cancer	0.000217	0.000531	CcSEcCtD
Flecainide—Haematuria—Doxorubicin—kidney cancer	0.000216	0.000529	CcSEcCtD
Flecainide—Body temperature increased—Paclitaxel—kidney cancer	0.000216	0.000529	CcSEcCtD
Flecainide—Abdominal pain—Paclitaxel—kidney cancer	0.000216	0.000529	CcSEcCtD
Flecainide—Headache—Vincristine—kidney cancer	0.000215	0.000528	CcSEcCtD
Flecainide—Anorexia—Capecitabine—kidney cancer	0.000214	0.000523	CcSEcCtD
Flecainide—Agranulocytosis—Doxorubicin—kidney cancer	0.000211	0.000518	CcSEcCtD
Flecainide—Hypotension—Capecitabine—kidney cancer	0.00021	0.000513	CcSEcCtD
Flecainide—Vomiting—Gemcitabine—kidney cancer	0.000207	0.000508	CcSEcCtD
Flecainide—Bradycardia—Doxorubicin—kidney cancer	0.000207	0.000507	CcSEcCtD
Flecainide—CYP2D6—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	0.000206	0.00347	CbGpPWpGaD
Flecainide—Rash—Gemcitabine—kidney cancer	0.000206	0.000504	CcSEcCtD
Flecainide—Dermatitis—Gemcitabine—kidney cancer	0.000206	0.000503	CcSEcCtD
Flecainide—Headache—Gemcitabine—kidney cancer	0.000204	0.000501	CcSEcCtD
Flecainide—Nausea—Vincristine—kidney cancer	0.000204	0.0005	CcSEcCtD
Flecainide—CYP2C9—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	0.000204	0.00344	CbGpPWpGaD
Flecainide—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000204	0.0005	CcSEcCtD
Flecainide—Insomnia—Capecitabine—kidney cancer	0.000203	0.000497	CcSEcCtD
Flecainide—Hypoaesthesia—Doxorubicin—kidney cancer	0.000202	0.000496	CcSEcCtD
Flecainide—Paraesthesia—Capecitabine—kidney cancer	0.000201	0.000493	CcSEcCtD
Flecainide—Dyspnoea—Capecitabine—kidney cancer	0.0002	0.000489	CcSEcCtD
Flecainide—CYP2D6—Biological oxidations—ALDH1A1—kidney cancer	0.000199	0.00335	CbGpPWpGaD
Flecainide—Dyspepsia—Capecitabine—kidney cancer	0.000197	0.000483	CcSEcCtD
Flecainide—CYP2C9—Biological oxidations—ALDH1A1—kidney cancer	0.000197	0.00332	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—PAK1—kidney cancer	0.000196	0.00331	CbGpPWpGaD
Flecainide—Visual impairment—Doxorubicin—kidney cancer	0.000196	0.00048	CcSEcCtD
Flecainide—Asthenia—Paclitaxel—kidney cancer	0.000196	0.00048	CcSEcCtD
Flecainide—Decreased appetite—Capecitabine—kidney cancer	0.000195	0.000477	CcSEcCtD
Flecainide—Nausea—Gemcitabine—kidney cancer	0.000194	0.000475	CcSEcCtD
Flecainide—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000194	0.000474	CcSEcCtD
Flecainide—Fatigue—Capecitabine—kidney cancer	0.000193	0.000473	CcSEcCtD
Flecainide—Pruritus—Paclitaxel—kidney cancer	0.000193	0.000473	CcSEcCtD
Flecainide—Pain—Capecitabine—kidney cancer	0.000192	0.000469	CcSEcCtD
Flecainide—Constipation—Capecitabine—kidney cancer	0.000192	0.000469	CcSEcCtD
Flecainide—Eye disorder—Doxorubicin—kidney cancer	0.00019	0.000465	CcSEcCtD
Flecainide—Tinnitus—Doxorubicin—kidney cancer	0.00019	0.000464	CcSEcCtD
Flecainide—Flushing—Doxorubicin—kidney cancer	0.000189	0.000462	CcSEcCtD
Flecainide—CYP2C9—Arachidonic acid metabolism—CYP1A1—kidney cancer	0.000188	0.00316	CbGpPWpGaD
Flecainide—Diarrhoea—Paclitaxel—kidney cancer	0.000187	0.000458	CcSEcCtD
Flecainide—SCN5A—Axon guidance—PAK1—kidney cancer	0.000186	0.00314	CbGpPWpGaD
Flecainide—Feeling abnormal—Capecitabine—kidney cancer	0.000185	0.000452	CcSEcCtD
Flecainide—Immune system disorder—Doxorubicin—kidney cancer	0.000184	0.00045	CcSEcCtD
Flecainide—Gastrointestinal pain—Capecitabine—kidney cancer	0.000183	0.000449	CcSEcCtD
Flecainide—Dizziness—Paclitaxel—kidney cancer	0.000181	0.000442	CcSEcCtD
Flecainide—Alopecia—Doxorubicin—kidney cancer	0.00018	0.00044	CcSEcCtD
Flecainide—Urticaria—Capecitabine—kidney cancer	0.000178	0.000436	CcSEcCtD
Flecainide—Body temperature increased—Capecitabine—kidney cancer	0.000177	0.000434	CcSEcCtD
Flecainide—Abdominal pain—Capecitabine—kidney cancer	0.000177	0.000434	CcSEcCtD
Flecainide—Flatulence—Doxorubicin—kidney cancer	0.000174	0.000427	CcSEcCtD
Flecainide—Tension—Doxorubicin—kidney cancer	0.000174	0.000425	CcSEcCtD
Flecainide—Vomiting—Paclitaxel—kidney cancer	0.000174	0.000425	CcSEcCtD
Flecainide—Dysgeusia—Doxorubicin—kidney cancer	0.000173	0.000425	CcSEcCtD
Flecainide—Rash—Paclitaxel—kidney cancer	0.000172	0.000422	CcSEcCtD
Flecainide—Dermatitis—Paclitaxel—kidney cancer	0.000172	0.000421	CcSEcCtD
Flecainide—Nervousness—Doxorubicin—kidney cancer	0.000172	0.000421	CcSEcCtD
Flecainide—SCN4A—Axon guidance—KDR—kidney cancer	0.000171	0.00288	CbGpPWpGaD
Flecainide—Headache—Paclitaxel—kidney cancer	0.000171	0.000419	CcSEcCtD
Flecainide—SCN4A—Axon guidance—MET—kidney cancer	0.000168	0.00282	CbGpPWpGaD
Flecainide—Vision blurred—Doxorubicin—kidney cancer	0.000167	0.000409	CcSEcCtD
Flecainide—Ill-defined disorder—Doxorubicin—kidney cancer	0.000164	0.000402	CcSEcCtD
Flecainide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	0.000164	0.00276	CbGpPWpGaD
Flecainide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	0.000162	0.00273	CbGpPWpGaD
Flecainide—Nausea—Paclitaxel—kidney cancer	0.000162	0.000397	CcSEcCtD
Flecainide—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	0.000162	0.00272	CbGpPWpGaD
Flecainide—Asthenia—Capecitabine—kidney cancer	0.000161	0.000394	CcSEcCtD
Flecainide—SCN5A—Developmental Biology—CTNNA1—kidney cancer	0.00016	0.0027	CbGpPWpGaD
Flecainide—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	0.00016	0.0027	CbGpPWpGaD
Flecainide—SCN5A—L1CAM interactions—MAPK3—kidney cancer	0.00016	0.00269	CbGpPWpGaD
Flecainide—Malaise—Doxorubicin—kidney cancer	0.00016	0.000391	CcSEcCtD
Flecainide—Vertigo—Doxorubicin—kidney cancer	0.000159	0.00039	CcSEcCtD
Flecainide—Syncope—Doxorubicin—kidney cancer	0.000159	0.000389	CcSEcCtD
Flecainide—Pruritus—Capecitabine—kidney cancer	0.000159	0.000388	CcSEcCtD
Flecainide—Leukopenia—Doxorubicin—kidney cancer	0.000159	0.000388	CcSEcCtD
Flecainide—Palpitations—Doxorubicin—kidney cancer	0.000156	0.000383	CcSEcCtD
Flecainide—Loss of consciousness—Doxorubicin—kidney cancer	0.000156	0.000381	CcSEcCtD
Flecainide—Cough—Doxorubicin—kidney cancer	0.000155	0.000378	CcSEcCtD
Flecainide—SCN5A—Developmental Biology—PAX6—kidney cancer	0.000153	0.00258	CbGpPWpGaD
Flecainide—Convulsion—Doxorubicin—kidney cancer	0.000153	0.000376	CcSEcCtD
Flecainide—Diarrhoea—Capecitabine—kidney cancer	0.000153	0.000376	CcSEcCtD
Flecainide—Hypertension—Doxorubicin—kidney cancer	0.000153	0.000374	CcSEcCtD
Flecainide—SCN5A—L1CAM interactions—MAPK1—kidney cancer	0.000152	0.00256	CbGpPWpGaD
Flecainide—Arthralgia—Doxorubicin—kidney cancer	0.000151	0.000369	CcSEcCtD
Flecainide—Myalgia—Doxorubicin—kidney cancer	0.000151	0.000369	CcSEcCtD
Flecainide—Chest pain—Doxorubicin—kidney cancer	0.000151	0.000369	CcSEcCtD
Flecainide—Anxiety—Doxorubicin—kidney cancer	0.00015	0.000368	CcSEcCtD
Flecainide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.00015	0.000367	CcSEcCtD
Flecainide—Discomfort—Doxorubicin—kidney cancer	0.000149	0.000365	CcSEcCtD
Flecainide—Dizziness—Capecitabine—kidney cancer	0.000148	0.000363	CcSEcCtD
Flecainide—Dry mouth—Doxorubicin—kidney cancer	0.000147	0.000361	CcSEcCtD
Flecainide—Confusional state—Doxorubicin—kidney cancer	0.000146	0.000357	CcSEcCtD
Flecainide—Oedema—Doxorubicin—kidney cancer	0.000145	0.000354	CcSEcCtD
Flecainide—Vomiting—Capecitabine—kidney cancer	0.000143	0.000349	CcSEcCtD
Flecainide—Shock—Doxorubicin—kidney cancer	0.000142	0.000348	CcSEcCtD
Flecainide—Nervous system disorder—Doxorubicin—kidney cancer	0.000142	0.000347	CcSEcCtD
Flecainide—Thrombocytopenia—Doxorubicin—kidney cancer	0.000142	0.000346	CcSEcCtD
Flecainide—Rash—Capecitabine—kidney cancer	0.000141	0.000346	CcSEcCtD
Flecainide—Dermatitis—Capecitabine—kidney cancer	0.000141	0.000346	CcSEcCtD
Flecainide—Tachycardia—Doxorubicin—kidney cancer	0.000141	0.000345	CcSEcCtD
Flecainide—Headache—Capecitabine—kidney cancer	0.00014	0.000344	CcSEcCtD
Flecainide—Skin disorder—Doxorubicin—kidney cancer	0.00014	0.000344	CcSEcCtD
Flecainide—Hyperhidrosis—Doxorubicin—kidney cancer	0.00014	0.000342	CcSEcCtD
Flecainide—Anorexia—Doxorubicin—kidney cancer	0.000138	0.000337	CcSEcCtD
Flecainide—Hypotension—Doxorubicin—kidney cancer	0.000135	0.000331	CcSEcCtD
Flecainide—Nausea—Capecitabine—kidney cancer	0.000133	0.000326	CcSEcCtD
Flecainide—SCN5A—Developmental Biology—PAK1—kidney cancer	0.000133	0.00224	CbGpPWpGaD
Flecainide—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	0.000133	0.00224	CbGpPWpGaD
Flecainide—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.000132	0.000322	CcSEcCtD
Flecainide—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	0.000132	0.00222	CbGpPWpGaD
Flecainide—SCN5A—SIDS Susceptibility Pathways—JUN—kidney cancer	0.000131	0.00221	CbGpPWpGaD
Flecainide—Insomnia—Doxorubicin—kidney cancer	0.000131	0.00032	CcSEcCtD
Flecainide—SCN5A—SIDS Susceptibility Pathways—CTNNB1—kidney cancer	0.00013	0.00219	CbGpPWpGaD
Flecainide—Paraesthesia—Doxorubicin—kidney cancer	0.00013	0.000318	CcSEcCtD
Flecainide—Dyspnoea—Doxorubicin—kidney cancer	0.000129	0.000315	CcSEcCtD
Flecainide—Somnolence—Doxorubicin—kidney cancer	0.000128	0.000315	CcSEcCtD
Flecainide—Dyspepsia—Doxorubicin—kidney cancer	0.000127	0.000311	CcSEcCtD
Flecainide—Decreased appetite—Doxorubicin—kidney cancer	0.000126	0.000308	CcSEcCtD
Flecainide—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000125	0.000306	CcSEcCtD
Flecainide—Fatigue—Doxorubicin—kidney cancer	0.000125	0.000305	CcSEcCtD
Flecainide—SCN4A—Axon guidance—RAF1—kidney cancer	0.000124	0.00208	CbGpPWpGaD
Flecainide—Pain—Doxorubicin—kidney cancer	0.000124	0.000303	CcSEcCtD
Flecainide—Constipation—Doxorubicin—kidney cancer	0.000124	0.000303	CcSEcCtD
Flecainide—SCN4A—Axon guidance—ERBB2—kidney cancer	0.000122	0.00206	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—KDR—kidney cancer	0.000122	0.00206	CbGpPWpGaD
Flecainide—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	0.000122	0.00206	CbGpPWpGaD
Flecainide—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	0.000121	0.00204	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—MET—kidney cancer	0.00012	0.00201	CbGpPWpGaD
Flecainide—Feeling abnormal—Doxorubicin—kidney cancer	0.000119	0.000292	CcSEcCtD
Flecainide—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000118	0.000289	CcSEcCtD
Flecainide—CYP2D6—Biological oxidations—GSTT1—kidney cancer	0.000117	0.00197	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—KDR—kidney cancer	0.000116	0.00195	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—GSTT1—kidney cancer	0.000116	0.00195	CbGpPWpGaD
Flecainide—Urticaria—Doxorubicin—kidney cancer	0.000115	0.000281	CcSEcCtD
Flecainide—SCN5A—SIDS Susceptibility Pathways—VEGFA—kidney cancer	0.000115	0.00193	CbGpPWpGaD
Flecainide—Body temperature increased—Doxorubicin—kidney cancer	0.000114	0.00028	CcSEcCtD
Flecainide—Abdominal pain—Doxorubicin—kidney cancer	0.000114	0.00028	CcSEcCtD
Flecainide—SCN5A—Axon guidance—MET—kidney cancer	0.000114	0.00191	CbGpPWpGaD
Flecainide—CYP2C9—Arachidonic acid metabolism—PTGS2—kidney cancer	0.000112	0.00188	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—PTGS1—kidney cancer	0.000109	0.00184	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—PTGS1—kidney cancer	0.000109	0.00183	CbGpPWpGaD
Flecainide—Asthenia—Doxorubicin—kidney cancer	0.000104	0.000254	CcSEcCtD
Flecainide—Pruritus—Doxorubicin—kidney cancer	0.000102	0.00025	CcSEcCtD
Flecainide—CYP2D6—Phase 1 - Functionalization of compounds—POMC—kidney cancer	9.9e-05	0.00167	CbGpPWpGaD
Flecainide—Diarrhoea—Doxorubicin—kidney cancer	9.89e-05	0.000242	CcSEcCtD
Flecainide—CYP2C9—Phase 1 - Functionalization of compounds—POMC—kidney cancer	9.81e-05	0.00165	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	9.57e-05	0.00161	CbGpPWpGaD
Flecainide—Dizziness—Doxorubicin—kidney cancer	9.56e-05	0.000234	CcSEcCtD
Flecainide—SCN4A—Axon guidance—VEGFA—kidney cancer	9.43e-05	0.00159	CbGpPWpGaD
Flecainide—Vomiting—Doxorubicin—kidney cancer	9.19e-05	0.000225	CcSEcCtD
Flecainide—Rash—Doxorubicin—kidney cancer	9.11e-05	0.000223	CcSEcCtD
Flecainide—Dermatitis—Doxorubicin—kidney cancer	9.1e-05	0.000223	CcSEcCtD
Flecainide—Headache—Doxorubicin—kidney cancer	9.05e-05	0.000222	CcSEcCtD
Flecainide—SCN4A—Axon guidance—MAPK3—kidney cancer	8.92e-05	0.0015	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—RAF1—kidney cancer	8.83e-05	0.00149	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—RELA—kidney cancer	8.79e-05	0.00148	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—ERBB2—kidney cancer	8.74e-05	0.00147	CbGpPWpGaD
Flecainide—Nausea—Doxorubicin—kidney cancer	8.58e-05	0.00021	CcSEcCtD
Flecainide—SCN4A—Axon guidance—MAPK1—kidney cancer	8.49e-05	0.00143	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—RAF1—kidney cancer	8.39e-05	0.00141	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—ERBB2—kidney cancer	8.3e-05	0.0014	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—KDR—kidney cancer	8.28e-05	0.00139	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—MET—kidney cancer	8.1e-05	0.00136	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—GSTP1—kidney cancer	8.1e-05	0.00136	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—GSTP1—kidney cancer	8.03e-05	0.00135	CbGpPWpGaD
Flecainide—SCN4A—Axon guidance—KRAS—kidney cancer	8.02e-05	0.00135	CbGpPWpGaD
Flecainide—CYP2D6—Metapathway biotransformation—GSTP1—kidney cancer	7.99e-05	0.00134	CbGpPWpGaD
Flecainide—CYP2C9—Metapathway biotransformation—GSTP1—kidney cancer	7.92e-05	0.00133	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—CTNNB1—kidney cancer	7.64e-05	0.00129	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—GSTM1—kidney cancer	7.44e-05	0.00125	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—GSTM1—kidney cancer	7.38e-05	0.00124	CbGpPWpGaD
Flecainide—CYP2D6—Metapathway biotransformation—GSTM1—kidney cancer	7.34e-05	0.00124	CbGpPWpGaD
Flecainide—CYP2C9—Metapathway biotransformation—GSTM1—kidney cancer	7.27e-05	0.00123	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—CYP1A1—kidney cancer	7.05e-05	0.00119	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—CYP1A1—kidney cancer	6.99e-05	0.00118	CbGpPWpGaD
Flecainide—CYP2D6—Metapathway biotransformation—CYP1A1—kidney cancer	6.96e-05	0.00117	CbGpPWpGaD
Flecainide—CYP2C9—Metapathway biotransformation—CYP1A1—kidney cancer	6.9e-05	0.00116	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—VEGFA—kidney cancer	6.73e-05	0.00113	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—VEGFA—kidney cancer	6.39e-05	0.00108	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—MAPK3—kidney cancer	6.37e-05	0.00107	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ACY1—kidney cancer	6.2e-05	0.00104	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ACY1—kidney cancer	6.15e-05	0.00104	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—MAPK1—kidney cancer	6.06e-05	0.00102	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—MAPK3—kidney cancer	6.05e-05	0.00102	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—RAF1—kidney cancer	5.99e-05	0.00101	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—RELA—kidney cancer	5.96e-05	0.001	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—ERBB2—kidney cancer	5.92e-05	0.000997	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—MAPK1—kidney cancer	5.75e-05	0.000969	CbGpPWpGaD
Flecainide—SCN4A—Developmental Biology—KRAS—kidney cancer	5.72e-05	0.000963	CbGpPWpGaD
Flecainide—SCN5A—Axon guidance—KRAS—kidney cancer	5.43e-05	0.000915	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PDHB—kidney cancer	5.28e-05	0.000888	CbGpPWpGaD
Flecainide—CYP2D6—Biological oxidations—POMC—kidney cancer	5.26e-05	0.000886	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	5.25e-05	0.000883	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PDHB—kidney cancer	5.23e-05	0.000881	CbGpPWpGaD
Flecainide—CYP2C9—Biological oxidations—POMC—kidney cancer	5.21e-05	0.000878	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—CTNNB1—kidney cancer	5.18e-05	0.000873	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CCBL1—kidney cancer	4.96e-05	0.000835	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CCBL1—kidney cancer	4.92e-05	0.000828	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—VEGFA—kidney cancer	4.56e-05	0.000768	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	4.45e-05	0.000749	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—MAPK3—kidney cancer	4.32e-05	0.000727	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GLIPR1—kidney cancer	4.3e-05	0.000724	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PPAT—kidney cancer	4.3e-05	0.000724	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PPAT—kidney cancer	4.26e-05	0.000718	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GLIPR1—kidney cancer	4.26e-05	0.000718	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	4.21e-05	0.000709	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	4.17e-05	0.000702	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—MAPK1—kidney cancer	4.11e-05	0.000691	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—APRT—kidney cancer	4e-05	0.000673	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—FH—kidney cancer	4e-05	0.000673	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—APRT—kidney cancer	3.96e-05	0.000667	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—FH—kidney cancer	3.96e-05	0.000667	CbGpPWpGaD
Flecainide—SCN5A—Developmental Biology—KRAS—kidney cancer	3.88e-05	0.000653	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	3.87e-05	0.000652	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GPC3—kidney cancer	3.76e-05	0.000633	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GPC3—kidney cancer	3.73e-05	0.000628	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CA2—kidney cancer	3.66e-05	0.000616	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CA2—kidney cancer	3.63e-05	0.00061	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ALAD—kidney cancer	3.56e-05	0.0006	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ALAD—kidney cancer	3.53e-05	0.000595	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ST3GAL2—kidney cancer	3.48e-05	0.000586	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ST3GAL2—kidney cancer	3.45e-05	0.000581	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ALDH1A1—kidney cancer	3.4e-05	0.000572	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ALDH1A1—kidney cancer	3.37e-05	0.000568	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PGK1—kidney cancer	3.26e-05	0.000549	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—SLC5A3—kidney cancer	3.26e-05	0.000549	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PGK1—kidney cancer	3.23e-05	0.000544	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—SLC5A3—kidney cancer	3.23e-05	0.000544	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—LDHB—kidney cancer	3.2e-05	0.000538	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—LDHB—kidney cancer	3.17e-05	0.000534	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CA9—kidney cancer	2.77e-05	0.000467	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CA9—kidney cancer	2.75e-05	0.000463	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	2.69e-05	0.000452	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CRABP1—kidney cancer	2.36e-05	0.000397	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CRABP1—kidney cancer	2.34e-05	0.000393	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ITPR2—kidney cancer	2.19e-05	0.000369	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ITPR2—kidney cancer	2.17e-05	0.000366	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	2e-05	0.000337	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GSTT1—kidney cancer	2e-05	0.000336	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ACHE—kidney cancer	2e-05	0.000336	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GSTT1—kidney cancer	1.98e-05	0.000333	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ACHE—kidney cancer	1.98e-05	0.000333	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—SCARB1—kidney cancer	1.89e-05	0.000318	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—SCARB1—kidney cancer	1.87e-05	0.000316	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PTGS1—kidney cancer	1.87e-05	0.000315	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PTGS1—kidney cancer	1.86e-05	0.000313	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PSMD7—kidney cancer	1.84e-05	0.000309	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PSMD7—kidney cancer	1.82e-05	0.000306	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—BCHE—kidney cancer	1.74e-05	0.000293	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—BCHE—kidney cancer	1.73e-05	0.000291	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—SLC5A5—kidney cancer	1.72e-05	0.000289	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—SLC5A5—kidney cancer	1.7e-05	0.000287	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—SLC2A1—kidney cancer	1.66e-05	0.00028	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—SLC2A1—kidney cancer	1.65e-05	0.000277	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.6e-05	0.000269	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.39e-05	0.000235	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GSTP1—kidney cancer	1.38e-05	0.000233	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GSTP1—kidney cancer	1.37e-05	0.000231	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—ABCB1—kidney cancer	1.31e-05	0.000221	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—ABCB1—kidney cancer	1.3e-05	0.000219	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—GSTM1—kidney cancer	1.27e-05	0.000214	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—GSTM1—kidney cancer	1.26e-05	0.000212	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—CYP1A1—kidney cancer	1.21e-05	0.000203	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—CYP1A1—kidney cancer	1.2e-05	0.000201	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	9.82e-06	0.000165	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—POMC—kidney cancer	8.99e-06	0.000151	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—POMC—kidney cancer	8.92e-06	0.00015	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PTGS2—kidney cancer	7.17e-06	0.000121	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PTGS2—kidney cancer	7.11e-06	0.00012	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PTEN—kidney cancer	6.26e-06	0.000105	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PTEN—kidney cancer	6.2e-06	0.000104	CbGpPWpGaD
Flecainide—CYP2D6—Metabolism—PIK3CA—kidney cancer	4.41e-06	7.43e-05	CbGpPWpGaD
Flecainide—CYP2C9—Metabolism—PIK3CA—kidney cancer	4.38e-06	7.37e-05	CbGpPWpGaD
